Does Ohio Medicaid Cover GLP-1 Weight Loss Drugs in 2026?

Last updated: June 25, 2026 | Reading time: ~8 minutes | Reviewed by Dr. Marcus Tan, MD

Direct answer — Ohio Medicaid and GLP-1s in 2026

As of 2026, Ohio Medicaid covers GLP-1 medications for type 2 diabetes — with prior authorization and a documented type 2 diabetes diagnosis on the claim — but it does not cover them for weight loss or obesity. Ohio Administrative Code rule 5160-9-03 categorically excludes “drugs for the treatment of obesity,” and the weight-management GLP-1s (Wegovy, Zepbound, Saxenda) are not on the Unified Preferred Drug List at all. Because all seven Ohio managed-care plans share the same statewide drug list, the answer is identical no matter which plan you have. The practical takeaway: a covered GLP-1 requires a real type 2 diabetes diagnosis, not a weight-loss goal.

Important — verify your specific plan

Formularies and prior-authorization criteria change. Before you fill a prescription, call the member-services number on the back of your Ohio Medicaid card (or your managed-care plan’s number) and check the current Ohio Medicaid Unified Preferred Drug List (UPDL). This guide summarizes the rules as of June 25, 2026; your prescriber’s office can confirm the exact prior-authorization requirements that apply to you today.

Ohio Medicaid GLP-1 coverage at a glance

Drug	FDA-Approved Indication	Ohio Medicaid Coverage 2026	Prior Authorization?
Ozempic	Type 2 diabetes	Covered, non-preferred	Yes (PA / step therapy)
Wegovy	Weight management	Not covered — obesity exclusion	n/a
Mounjaro	Type 2 diabetes	Covered, non-preferred	Yes (PA / step therapy)
Zepbound	Weight management	Not covered — obesity exclusion	n/a
Trulicity	Type 2 diabetes	Covered, preferred	Often
Victoza	Type 2 diabetes	Covered, preferred	Often

GLP-1s for type 2 diabetes on Ohio Medicaid

If you have type 2 diabetes, Ohio Medicaid does cover GLP-1 receptor agonists — but the route to a filled prescription depends on which drug your prescriber chooses. Ohio runs a single statewide pharmacy benefit through its Single Pharmacy Benefit Manager (Gainwell SPBM) and one Unified Preferred Drug List (UPDL). All seven managed-care plans (CareSource, Buckeye, Molina, UnitedHealthcare Community Plan, AmeriHealth Caritas, Anthem, and Humana Healthy Horizons) use that same drug list. So the question “does my plan cover Ozempic” is really just the Ohio Medicaid question.

The UPDL splits diabetes GLP-1s into preferred and non-preferred agents:

Preferred (the first-line options): Trulicity, Victoza, and Byetta.
Non-preferred (require prior authorization to override, often after trying a preferred agent first): Ozempic, Mounjaro, Rybelsus, and Bydureon BCise.

A significant change took effect on December 8, 2025: claims for GLP-1 medications now require a documented type 2 diabetes diagnosis. In plain terms, the type 2 diabetes ICD-10 code has to be on the claim for the drug to pay. This diagnosis gate is the single most important thing to get right, and it is now the leading cause of GLP-1 denials in Ohio.

For a non-preferred agent like Ozempic or Mounjaro, expect a clinical prior authorization and possibly step therapy — meaning you may need to show that a preferred GLP-1 such as Trulicity or Victoza was tried first or isn’t appropriate for you. The specific clinical criteria can vary, so confirm the current requirements with your plan before filling.

Wegovy & Zepbound for weight loss on Ohio Medicaid

This is where many members are surprised. Ohio Medicaid does not cover Wegovy, Zepbound, or Saxenda for weight loss. There are two reasons, and they reinforce each other:

The regulatory exclusion. Ohio Administrative Code rule 5160-9-03 categorically excludes “drugs for the treatment of obesity” from coverage. This is a rule-level exclusion, not a per-case decision.
They aren’t on the list. The weight-management GLP-1s simply do not appear on the Unified Preferred Drug List, so there is no preferred or non-preferred pathway to request.

Because this is a regulatory exclusion rather than a discretionary denial, a “weight-loss only” request can’t be appealed into coverage. There is no clinical letter or peer-to-peer review that overrides a rule that says obesity drugs are excluded. If you have type 2 diabetes alongside obesity, the path to a covered GLP-1 is through the diabetes indication — not the weight-loss one.

Ozempic / Mounjaro off-label for weight loss

A common question is whether a prescriber can get a diabetes GLP-1 like Ozempic or Mounjaro covered “off-label” for weight loss. Since December 8, 2025, the answer is effectively no. The diagnosis gate requires a documented type 2 diabetes diagnosis on the claim, so an off-label weight-loss prescription will not clear prior authorization. Even though Ozempic and Mounjaro are on the UPDL, they only pay when tied to type 2 diabetes. Without that diagnosis, the prior authorization fails at the gate.

If you don’t have type 2 diabetes, off-label use through Ohio Medicaid is not a realistic path. The alternatives below are the more practical options.

What if Ohio Medicaid denies your GLP-1?

If you have type 2 diabetes and your GLP-1 was still denied, work through these steps in order:

1. Check the diagnosis on the claim. Make sure the type 2 diabetes ICD-10 diagnosis is actually on the claim. A missing diagnosis code has been the number-one denial cause since December 2025, and it’s often a quick fix at the prescriber’s office.
2. Switch to a preferred agent. If you were prescribed a non-preferred drug, ask whether a preferred GLP-1 such as Trulicity or Victoza would work for you. Preferred agents face fewer hurdles.
3. Request an internal appeal. Ask your managed-care plan (MCO) for an internal appeal, and have your prescriber submit a peer-to-peer review or a letter of medical necessity documenting your diabetes and treatment history.
4. Request a State Hearing. If the internal appeal fails, you can request a State Hearing through the Ohio Department of Job and Family Services (ODJFS) Bureau of State Hearings. Confirm the exact deadline printed on your denial notice — it’s typically around 90 days, but always follow the date on your notice.

One important caveat: a denial for weight loss only is not appealable into coverage, because it stems from the regulatory obesity exclusion described above. Appeals are meaningful for diabetes coverage decisions, not for the weight-loss exclusion.

GLP-1 alternatives for Ohio Medicaid members

If you want a GLP-1 for weight loss and Ohio Medicaid won’t cover it, two paths exist outside the Medicaid benefit. Cash-pay telehealth programs offer compounded semaglutide or tirzepatide, generally in the range of roughly $200-$400 per month. Note that compounded versions are not FDA-approved and are not Medicaid-covered. Separately, manufacturer patient-assistance programs may help with brand-name drugs, but be aware that most manufacturer copay cards explicitly exclude Medicaid patients.

Ro Body Program

A telehealth weight-management program with clinician visits and access to GLP-1 options for eligible patients on a cash-pay basis. A common starting point for members whose Medicaid plan won’t cover weight-loss GLP-1s.

Remedy Meds

A cash-pay telehealth option offering compounded GLP-1 medications with monthly pricing. Useful to compare against other programs before you commit.

See Remedy Meds pricing

Want to weigh your options side by side? Compare GLP-1 telehealth programs on price, drug type, and what's included.

How to apply for prior authorization

If you have type 2 diabetes and need a non-preferred GLP-1, here's the generic Ohio Medicaid prior-authorization workflow:

1. Confirm your type 2 diabetes diagnosis is documented in your chart and will appear on the claim.
2. Have your prescriber check the current UPDL to see whether your drug is preferred or non-preferred.
3. For a non-preferred agent, your prescriber submits a prior-authorization request to the Ohio Medicaid pharmacy benefit, including diagnosis, prior treatments tried, and clinical rationale.
4. If step therapy applies, document any preferred GLP-1 that was tried or any reason a preferred agent isn't appropriate.
5. Watch for the decision. If it's denied, follow the appeal steps above starting with verifying the diagnosis code.

Frequently asked questions

Does Ohio Medicaid cover Wegovy for weight loss?

No. Wegovy is not covered for weight loss. Ohio Administrative Code rule 5160-9-03 excludes drugs used to treat obesity, and Wegovy is not on the Unified Preferred Drug List. Because this is a regulatory exclusion, a weight-loss-only request can't be appealed into coverage.

Does Ohio Medicaid cover Ozempic?

Yes, for type 2 diabetes. Ozempic is on the UPDL as a non-preferred agent, so it requires prior authorization (and possibly step therapy through a preferred GLP-1). Since December 8, 2025, the claim must include a documented type 2 diabetes diagnosis. It is not covered for weight loss.

Does CareSource cover Ozempic or Mounjaro?

CareSource follows the same statewide Ohio Medicaid Unified Preferred Drug List as every other managed-care plan, so the answer is the same as for Ohio Medicaid overall: Ozempic and Mounjaro are covered for type 2 diabetes as non-preferred agents (with prior authorization), and not covered for weight loss.

Does Ohio Medicaid cover Zepbound?

No. Zepbound is approved for weight management, which falls under the obesity exclusion in OAC 5160-9-03, and it is not on the UPDL. If you have type 2 diabetes, Mounjaro (the same active ingredient, approved for diabetes) is the covered pathway, subject to prior authorization.

How do I appeal an Ohio Medicaid GLP-1 denial?

First confirm the type 2 diabetes diagnosis is on the claim — that's the most common fix. If the diagnosis is correct, request an internal appeal with your managed-care plan and have your prescriber submit a peer-to-peer review or letter of medical necessity. If that fails, request a State Hearing through ODJFS, following the deadline on your denial notice (typically around 90 days). Weight-loss-only denials are not appealable into coverage.

Are there cheaper GLP-1 options if Ohio Medicaid won't cover it?

Yes. Cash-pay telehealth programs offer compounded semaglutide or tirzepatide for roughly $200-$400 per month, though compounded versions are not FDA-approved and not Medicaid-covered. Manufacturer patient-assistance programs may help with brand drugs, but most manufacturer copay cards exclude Medicaid patients. You can compare GLP-1 telehealth programs to find the best fit.